MCOLN1 and neoplasm: Innovative strategies include exploiting cancer-specific aberrations (e.g. activating TRPML1, upregulated in some cancers, to induce lysozincrosis selectively in cancer cells [137] and localizing treatment via nanoparticles or tumor enzyme-activated prodrugs.